Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncolys Submits IND  For Anti-HIV Drug Festinavir

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Oncolys BioPharma submitted an Investigative New Drug application for anti-HIV drugFestinavir (OBP-601) to the U.S. FDA, to gain permission to initiate Phase I trials. Festinavir is a novel anti-HIV drug with a mechanism for inhibiting nucleotide reverse transcriptase, which is essential for human immune-deficiency virus replication. Based on preclinical studies, Festinavirshows comparable or superior efficacy and safety versus existing NRTIs and could become a potential best-in-class drug for combination in a highly active antiretroviral therapy. Oncolys in-licensed worldwide rights to Festinavir from Yale University in June 2006. (Click here for more-J apanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts